-Advances Reported in All Three Clinical Programs, Including Launch of Key
Bavituximab Phase II Cancer Program-
TUSTIN, Calif., March 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced financial results for the third quarter of fiscal year (FY) 2008 ended January 31, 2008. The company reported a consolidated net loss of $6,154,000, or $0.03 per basic and diluted share, compared to a consolidated net loss of $5,025,000 or $0.03 per basic and diluted share for the same prior year period. The increased net loss primarily reflects increased investments in research and development as the company advanced its clinical programs for bavituximab and Cotara(R).
Total revenues for the current quarter increased to $1,675,000 compared to $363,000 for the comparable quarter last year, and were primarily generated from services provided by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.
Total costs and expenses increased to $8,077,000 in the third quarter
of FY 2008 from $5,643,000 in the same prior year quarter. The increase was
primarily related to the increase in the cost of contract manufacturing of
$1,066,000 during the quarter resulting from higher reported revenues from
external customers, in addition to the increase in research and development
expenses of $1,034,000 associated with the advancement of the company's
clinical and preclinical product candidates. Research and development
expenses were $4,941,000 in the third quarter of FY 2008, compared to
$3,907,000 in the third quarter of FY 2007
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved